Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease.
Giardina, P.J. & Grady, R.W. (2010) Combined iron chelation therapy. Annals of the New York Academy of Sciences, 1202, 79–86. Jetsrisuparb, A., Komvilaisak, P., Wiangnon, S. & Jetsrisuparb, C. (2010) Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. Journal of Pediatric Hematology Oncology, 32, 400–403. Otto-Duessel, M., Brewer, C., Gonzalez, I., Nick, H. & Wood, J.C. (2008) Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematologica, 120, 123–128. Roberts, D.J., Brunskill, S.J., Doree, C., Williams, S., Howard, J. & Hyde, C.J. (2007) Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database of Systematic Reviews, 18;(3): CD004839. Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Pibiri, M., Nair, S.V., Walker, J.M. & Pennell, D.J. (2008) Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. Journal of Cardiovascular Magnetic Resonance, 10, 12. Voskaridou, E., Douskou, M., Terpos, E., Papassotiriou, I., Stamoulakatou, A., Ourailidis, A., Loutradi, A. & Loukopoulos, D. (2004) Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. British Journal of Haematology, 126, 736–742.